Veterinary Therapeutics最新文献

Hydrochlorothiazide (1 mg/kg PO q12h) or placebo was administered to healthy cats for 2 weeks in a masked, placebo-controlled, crossover-design study, and 24-hour urine samples were collected. When cats received hydrochlorothiazide, 24-hour urine volume, ammonia, chloride, creatinine, magnesium, oxalic acid, phosphate, potassium, and sodium were significantly higher than when cats received placebo. Hydrochlorothiazide was associated with significantly lower urinary saturation for calcium oxalate, but no difference was found in 24-hour urine calcium and citrate, urinary saturation for struvite, or blood ionized calcium. Hydrochlorothiazide decreased urinary saturation for calcium oxalate and could be useful in managing cats with calcium oxalate uroliths. Results of this study, however, should not be extrapolated to cats that form calcium oxalate uroliths.

A study was conducted to assess the effectiveness (fecal egg count reductions) and benefit (improvement in feed efficiency, average daily gain, health, and so forth) of a macrocyclic lactone (moxidectin [Cydectin Injectable] or doramectin [Dectomax 1% Injectable]) alone or in combination with a benzimidazole (oxfendazole [Synanthic Bovine Dewormer]) as used in steers upon their arrival at a feedlot. The cattle were kept in the feedlot for 181 days. Only minor differences in fecal egg count reductions were seen among treatments, with all egg counts reduced by more than 98% by 28 days posttreatment. Likewise, no statistically significant differences among treatments were seen in terms of animal performance (feed efficiency, intake, gain, morbidity, mortality, and carcass quality). All three treatment regimens appear to be comparable in decreasing nematode burdens and the consequences thereof in feedlot cattle.

T evaluate the effect of supplementation with Enterococcus faecium strain SF68 (NCIMB10415) on immune function, responses to a multivalent vaccine were investigated in kittens given palatability enhancer with or without E. faecium SF68 daily. E. faecium SF68 was detected in the feces of seven of nine treated cats. Supplementation of kittens with E. faecium SF68 did not affect developmental parameters. The percentage of CD4+ lymphocytes was significantly higher in the treatment group. There were no statistical differences in measurements of any other nonspecific or specific immune parameters between groups.

Analgesics given preoperatively have the potential to decrease the amount of inhalant anesthetics required intraoperatively (i.e., to decrease the minimum alveolar concentration, or MAC, for the inhalant). Tepoxalin is an NSAID approved for the treatment of arthritis in dogs in the United States and, hence, could be administered to patients undergoing anesthesia. In this study, administration of a single dose or a 10-day course of tepoxalin did not affect the MAC for isoflurane or sevoflurane.

Using a randomized crossover design, this study compared the anesthetic and cardiorespiratory effects of three intramuscular anesthetic combinations in seven 2-year-old cats: tiletamine-zolazepam (8 mg/kg) and butorphanol (0.2 mg/kg) (TT); tiletamine-zolazepam (3 mg/kg), butorphanol (0.15 mg/kg), and medetomidine (15 microg/kg) (TTD); or the TTD protocol plus atipamezole (75 microg/kg IM) given 20 minutes later to reverse medetomidine. Analgesia was assessed using algometry and needle pricking. All three combinations effectively induced anesthesia suitable for orotracheal intubation within 5 minutes after injection. Hemoglobin oxygen saturation was lower than 90% at least once in all three groups between 5 and 15 minutes after drug administration. Blood pressure and heart and respiratory rates were within normal ranges. Both TT and TTD appeared to be effective injectable anesthetic combinations. TTD provided significantly better analgesia with a longer duration than did TT. Atipamezole administration shortened the duration of analgesia and decreased blood pressure but did not shorten total recovery time.

Heartworm infection in dogs and cats in the western United States is a fairly new phenomenon, and for this reason it is often considered to be of minimal significance. The purpose of this survey was to collect data from 11 western states (Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming) in an effort to assess awareness of heartworm disease and identify areas in which improvement in understanding is needed. To accomplish this goal, veterinary clinics and hospitals in these states were sent a one-page survey in early 2006. The results of the survey demonstrate that cases of heartworm disease have been reported in all 11 states, illustrating the importance of annual testing and the routine use of preventives.

The safety of a feed-thru pellet formulation containing the insect growth regulator diflubenzuron (0.24%) for control of manure-breeding flies (Musca domestica L. and Stomoxys calcitrans L.) in horses was evaluated. Pellets were administered orally at 0, 1, 3, and 5 times the clinical dosage (0.12 to 0.20 mg/kg) on a daily basis for 31 consecutive days. Variables examined included daily clinical observations, hematology, coagulation, serum chemistry, acetylcholinesterase inhibition, body weights, and physical examinations. Horses remained healthy throughout the study, and no adverse reactions or events related to the pellets were observed. Statistically significant differences (P < or = 0.10) between dose groups (0x, 1x, 3x, and 5x) were observed for only four of the 44 serum chemistry and hematologic variables measured, none of which was dose related. Diflubenzuron can be safely administered orally to horses at 0.12 to 0.20 mg/kg for control of manure-breeding flies.

Veterinarians currently have a choice of six registered NSAIDs for use in the management of canine osteoarthritis. There is a need for data to clarify whether there is an increased risk of side effects occurring in the event of a switch between different members of the NSAID class. In this retrospective analysis of extensive data collected in the 1,000 dog Previcox (firocoxib, Merial) Experience Trial, the incidence of side effects in dogs reported as treated with an NSAID 7 days or less before enrollment was compared with that in dogs reported as not having received an NSAID in the equivalent period. Statistical analysis of the data indicates that observation of an interval of up to 1 week between beginning treatment with firocoxib and cessation of treatment with a different NSAID was not associated with any increased risk of adverse events.

This study compared anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol (TT), tiletamine-zolazepam-butorphanol-medetomidine (TTD), and tiletamine-zolazepam-butorphanol-medetomidine with atipamezole reversal 1 hour after TTD administration in dogs. All dogs received glycopyrrolate. All drug combinations effectively induced anesthesia within 5 minutes after IM injection. Duration of analgesia was 40 to 60 minutes. Recovery was smooth, but the overall quality of recovery was poorer in the TT group. Hypoxia occurred with some dogs in the TTD group at 5 minutes. TTD provided better analgesia with longer duration and better recovery quality compared with TT. Reversal of TTD with atipamezole was not effective in shortening recovery time.

Medications given preoperatively have the potential to affect the induction dose of injectable anesthetics, which could result in an anesthetic overdose. Tepoxalin is an NSAID approved for the treatment of arthritis in dogs in the United States and hence could be administered in patients requiring anesthesia. In this study, administration of a single dose or a 10-day course of tepoxalin did not affect the induction dose (dose that allowed intubation) of propofol, thiopental, or ketamine-diazepam and also did not affect the time required for dogs to recover from anesthesia.